Transthyretin (ATTR) Amyloidosis
View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.
Congresses
Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)
European Society of Cardiology (ESC) 2026
Transthyretin Amyloidosis (ATTR)
RNA Therapeutics Symposium (RNATx) 2026
Transthyretin Amyloidosis (ATTR)
Peripheral Nerve Society (PNS) 2026
Transthyretin Amyloidosis (ATTR)
Heart Failure Association (HFA) 2026
Transthyretin Amyloidosis (ATTR)
American Academy of Neurology (AAN) 2026
Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)
American College of Cardiology (ACC) 2026
Publications
Transthyretin Amyloidosis (ATTR)
Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy: Insights From HELIOS-B
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI
Journal of the American Medical Association
Transthyretin Amyloidosis (ATTR)
Comorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights From the HELIOS-B Trial
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial
European Journal of Heart Failure
